Neurocrine Biosciences, Inc. Share Price BOERSE MUENCHEN
Equities
NB3
US64125C1099
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
124.8 EUR | +2.97% | +0.12% | +3.92% |
Sales 2024 * | 2.22B 2.05B 174B | Sales 2025 * | 2.55B 2.36B 201B | Capitalization | 13.58B 12.58B 1,068B |
---|---|---|---|---|---|
Net income 2024 * | 431M 399M 33.88B | Net income 2025 * | 675M 625M 53.06B | EV / Sales 2024 * | 5.22 x |
Net cash position 2024 * | 2B 1.85B 157B | Net cash position 2025 * | 2.81B 2.6B 221B | EV / Sales 2025 * | 4.22 x |
P/E ratio 2024 * |
33.3
x | P/E ratio 2025 * |
21.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
1 week | +0.12% | ||
Current month | +0.12% | ||
1 month | -6.38% | ||
3 months | +0.97% | ||
6 months | +12.59% | ||
Current year | +3.92% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 31/12/91 |
Director of Finance/CFO | 44 | 31/10/17 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 29/11/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 31/03/99 |
George Morrow
BRD | Director/Board Member | 72 | 30/09/15 |
Kevin Gorman
FOU | Founder | 66 | 31/12/91 |
Date | Price | Change |
---|---|---|
07/06/24 | 124.8 | +2.97% |
06/06/24 | 121.2 | -2.06% |
05/06/24 | 123.7 | +0.04% |
04/06/24 | 123.6 | -3.77% |
03/06/24 | 128.5 | +3.13% |
Real-time BOERSE MUENCHEN, June 07, 2024 at 08:43 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+27.89% | 11.66B | |
+83.45% | 9.17B |
- Stock Market
- Equities
- NBIX Stock
- NB3 Stock